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We have reported that tyrosine-phosphorylated forms of a cellular protein, FKBP52, inhibit the second-strand DNA synthesis of adeno-
associated virus 2 (AAV), leading to inefficient transgene expression from recombinant AAV vectors. To further explore the role of FKBP52 in
AAV-mediated transduction, we established murine embryo fibroblasts (MEFs) cultures from FKBP52 wild-type (WT), heterozygous (HE), and
knockout (KO) mice. Conventional AAV vectors failed to transduce WT MEFs efficiently, and the transduction efficiency was not significantly
increased in HE or KO MEFs. AAV vectors failed to traffic efficiently to the nucleus in these cells. Treatment with hydroxyurea (HU) increased
the transduction efficiency of conventional AAV vectors by ∼25-fold in WT MEFs, but only by ∼4-fold in KO MEFs. The use of self-
complementary AAV (scAAV) vectors, which bypass the requirement of viral second-strand DNA synthesis, revealed that HU treatment increased
the transduction efficiency ∼23-fold in WT MEFs, but only ∼4-fold in KO MEFs, indicating that the lack of HU treatment-mediated increase in
KO MEFs was not due to failure of AAV to undergo viral second-strand DNA synthesis. Following HU treatment, ∼59% of AAV genomes were
present in the nuclear fraction from WT MEFs, but only ∼28% in KO MEFs, indicating that the pathway by which HU treatment mediates nuclear
transport of AAV was impaired in KO MEFs. When KO MEFs were stably transfected with an FKBP52 expression plasmid, HU treatment-
mediated increase in the transduction efficiency was restored in these cells, which correlated directly with improved intracellular trafficking. Intact
AAV particles were also shown to interact with FKBP52 as well as with dynein, a known cellular protein involved in AAV trafficking. These
studies suggest that FKBP52, being a cellular chaperone protein, facilitates intracellular trafficking of AAV, which has implications in the optimal
use of recombinant AAV vectors in human gene therapy.
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Adeno-associated virus 2 (AAV), a nonpathogenic human
parvovirus, has gained attention as a potentially safe vector for
gene transfer and gene therapy (Conlon and Flotte, 2004;
Marshall, 2001). The AAV genome is a single-stranded DNA
(Berns and Giraud, 1996; Muzyczka, 1992), which is
284 W. Zhao et al. / Virology 353 (2006) 283–293transcriptionally inactive. Others and we have suggested that
viral second-strand DNA synthesis is the rate-limiting step in
AAV-mediated transgene expression (Ferrari et al., 1996; Fisher
et al., 1996; Mah et al., 1998; Qing et al., 1997, 1998, 2001,
2003; Zhong et al., 2004a, 2004b, 2004c, 2004d). In our
previous studies, we have identified that a 52-kDa cellular
protein, FKBP52, which binds the immunosuppressant drug,
FK506, interacts specifically with the D-sequence within the
inverted terminal repeat (ITR) of the AAV genome (Qing et al.,
2001; Zhong et al., 2004a, 2004b, 2004c, 2004d). FKBP52 is
phosphorylated at both tyrosine and serine or threonine
residues, and phosphorylated FKBP52 inhibits the viral
second-strand DNA synthesis, leading to inefficient transgene
expression (Mah et al., 1998; Qing et al., 1997, 1998, 2001,
2003; Zhong et al., 2004a, 2004b, 2004c, 2004d). We have also
documented that FKBP52 is dephosphorylated at tyrosine
residues by the cellular T cell protein tyrosine phosphatase (TC-
PTP), and dephosphorylated FKBP52 can no longer bind to the
D-sequence, thereby allowing viral second-strand DNA syn-
thesis and, consequently, efficient transgene expression (Qing
et al., 2003; Zhong et al., 2004a, 2004b, 2004c, 2004d).
Our previous studies with FKBP52-knockout (FKBP52-KO)
mice, in which FKBP52 is completely absent, documented that
the transduction efficiency in hematopoietic stem/progenitor
cells and hepatocytes was significantly less pronounced than
that from TC-PTP-transgenic (TC-PTP-TG) mice, in which
FKBP52 is dephoshorylated at tyrosine residues (Zhong et al.,
2004a, 2004b, 2004c). We have also reported that AAV vectors
transduce an established murine fibroblast cell line poorly due
to impaired intracellular trafficking (Hansen et al., 2000,
2001a), and that deliberate over-expression of FKBP52
significantly increases the transduction efficiency in these
cells (Qing et al., 2001). Although we interpreted these data to
suggest that over-expression of FKBP52 led to dephosphory-
lation at tyrosine residues of the endogenous FKBP52 in the
nucleus, the precise role of FKBP52 in the cytoplasm remained
unclear. This is of significance since FKBP52 has been
documented to interact with HSP90 only when in the dephos-
phorylated form, and this complex has been shown to mediate
cytoplasmic transport of a number of cellular and viral proteins
to the nucleus (Czar et al., 1994a, 1994b; Denny et al., 2005;
Perrot-Applanat et al., 1995; Pratt, 1998; Pratt et al., 1999,
2004; Pratt and Toft, 1997; Wochnik et al., 2005; Wu et al.,
2004). FKBP52 is a cellular chaperone protein, and ∼80% is
localized in the nucleus, and ∼20% in cytoplasm, where it co-
localizes with microtubules and dynein, a retrograde motor
protein, where the PPIase domain fragment of FKBP52 interacts
with dynein (Czar et al., 1994a, 1994b; Perrot-Applanat et al.,
1995). Thus, in addition to studying the interaction of FKBP52
with the D-sequence in the AAV ITR, and its role in inhibiting
viral second-strand DNA synthesis in the nucleus, we also
wished to examine the role of FKBP52 present in the cytoplasm
in AAV-mediated transduction. To this end, we generated
primary mouse embryo fibroblasts (MEFs) from FKBP52-wild-
type (WT), heterozygous (HE), and knockout (KO) mice, and
examined various steps in the life cycle of recombinant AAV
vectors in these cells under a variety of conditions.Our studies reported here suggest that, in MEFs, AAV
vectors fail to gain entry into the nucleus. Treatment with
hydroxyurea (HU) promotes AAV nuclear transport, and
FKBP52 can facilitate this process. Thus, in addition to
interacting with the D-sequence in the AAV ITR, and inhibiting
viral second-strand DNA synthesis in the nucleus, FKBP52,
being a cellular chaperone protein, also facilitates intracellular
trafficking of AAV, which has implications in the optimal use of
recombinant AAV vectors in human gene therapy.
Results
MEFs from WT as well as KO mice are transduced poorly by
AAV vectors, which is not due to compensatory binding of a
cellular protein to the AAV D-sequence
Murine embryo fibroblasts (MEFs) from FKBP52 wild-
type (WT), heterozygous (HE), and knockout (KO) mice,
established following immortalization using wild-type SV40
virus infections, were either mock infected or infected with a
recombinant AAV2-lacZ vectors under identical conditions. β-
galactosidase activity was measured 48 h post-infection. These
results are shown in Fig. 1A. As is evident, no transgene
expression was detected in mock-infected cells, and the
transduction efficiency in WT MEFs was low. Although
reduction in the levels of FKBP52 in HE and complete
absence in KO MEFs were expected to augment viral second-
stranded DNA synthesis, the transduction efficiency of AAV
vectors was not significantly increased in HE and KO cells.
The lack of transgene expression was not a consequence of
immortalization by SV40 virus infection since primary MEFs
from these mice were also transduced poorly by AAV vectors
(data not shown). We next wished to determine whether
compensatory binding of a putative cellular protein to the
AAV D-sequence in the absence of FKBP52 in KO MEFs was
responsible for impaired viral second-strand DNA synthesis.
To this end, electrophoretic mobility shift assays (EMSA)
were performed using WCEs prepared from MEFs of each
genotype. These results are shown in Fig. 1B. As can be seen,
the AAV D-sequence probe (Lane 1) formed a complex only
with WCEs from WT (Lane 4), and to ∼50% lesser extent in
HE MEFs (Lane 3). No complex formation was detected with
WCEs from KO MEFs (Lane 2). These data suggested that, in
the absence of FKBP52, the observed lack of AAV-mediated
transgene expression in KO MEFs was not due to the presence
of a cellular protein that compensated for binding to the AAV
D-sequence leading to impaired viral second-strand DNA
synthesis.
The lack of AAV-mediated transgene expression in MEFs is not
due to the absence of cellular receptor and co-receptor
required for viral binding and entry
Since it remained possible that suboptimal levels of
expression of heparan sulfate proteoglycan (HSPG) and
fibroblast growth factor receptor 1 (FGFR1), the cellular
receptor and co-receptor, respectively, for AAV (Summerford
Fig. 1. (A) Comparative analyses of AAV-mediated transduction efficiency in MEFs from FKBP52-WT, HE, and KO mice. Approximately 3 × 105 MEFs were plated
in each well in a 6-well plate. Cells were either mock-infected or infected with 5 × 103 particles/cell of AAV2-lacZ under identical conditions. Cells were fixed, stained
with X-gal 48 h post-infection, and photographed using a Nikon inverted light microscope. Original magnification, 100×. (B) Electrophoretic mobility shift assays for
interaction between AAV D-sequence and WCEs of MEFs from three FKBP52 genotypes mice. The radiolabeled AAV D-sequence probe (Lane 1) forms a complex
when incubated with WCEs of MEFs from FKBP52-WTmice (Lane 4), but does not interact with those from FKBP52-KOmice (Lane 2), and the interaction with that
from FKBP52-HE mice is reduced by ∼50% (Lane 3). Complex of FKBP52 and D-sequence probe is denoted by the arrow.
285W. Zhao et al. / Virology 353 (2006) 283–293and Samulski, 1998; Qing et al., 1999), were responsible for
inefficient viral binding and entry into MEFs, we next
performed fluorescence-activated cell sorting (FACS) analyses,
the results of which are shown in Fig. 2A. It is clear that
∼41.14%, 46.44%, and 49.51% of MEFs from WT, HE, and
KO mice, respectively, expressed HSPG. Approximately
61.74%, 66.54%, and 63.82% of MEFs from WT, HE, and
KO mice, respectively, expressed FGFR1. Although we did not
analyze these cells for co-expression of HSPG and FGFR1, we
performed Southern blot analyses to detect entry of viral DNA.Fig. 2. (A) Comparative analyses of the levels of cell surface expression of heparan s
NIH3T3 cells and MEFs from FKBP52-WT, HE, and KO mice by fluorescence-activ
into MEFs from FKBP52-KO, HE, andWTmice. MEFs from each genotype were inf
isolated and analyzed by Southern blot hybridization using a 32P-labeled lacZ-speciBriefly, equivalent numbers of each cell type were infected with
a recombinant AAV-lacZ vector for 2 h at 37 °C and treated with
trypsin to degrade any adsorbed viral particles. Low Mr DNA
samples were analyzed on Southern blots using a lacZ-specific
DNA probe. These results are shown in Fig. 2B. The fact that
roughly the same level of hybridization to input single-stranded
AAV genomes was detected, these data corroborate that AAV
could efficiently enter MEFs from each of the three genotypes.
Thus, the absence of FKBP52 did not appear to influence viral
binding and entry into KO cells.ulfate proteoglycan (HSPG) and fibroblast growth factor receptor 1 (FGFR1) in
ated cell sorting (FACS). (B) Southern blot analyses of the AAV-lacZ DNA entry
ected with 3 × 103 particles/cell of AAV2-lacZ for 2 h at 37 °C. LowMr DNAwas
fic DNA probe. ssDNA denotes the viral single-stranded DNA genomes.
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of conventional, single-stranded AAV vectors in WT and HE
MEFs, but to a lesser extent in KO MEFs
Hydroxyurea (HU) is a chemotherapeutic agent and its
mechanism of action is believed to be based on its inhibition of
the enzyme ribonucleotide reductase. It has been reported that
HU treatment increases AAV-mediated transduction of many
cell types by causing S-phase arrest with a concomitant increase
in the DNA repair synthesis, which may be crucial for viral
second-strand DNA synthesis (Russell et al., 1995). However,
mechanisms other than inhibition of ribonucleotide reductase
might be responsible for increasing AAV-mediated transduction.
For example, we have reported that the transduction efficiency
of AAV vectors can be significantly augmented in the murine
established fibroblast cell line, NIH3T3, and in primary
hematopoietic stem/progenitor cells following treatment with
HU, because HU facilitates nuclear transport of AAV in these
cells (Hansen et al., 2001a; Zhong et al., 2004c) as well as leads
to dephosphorylation of FKBP52 at tyrosine residues (Qing et
al., 1997, 1998; Mah et al., 1998). We wished to examine
whether HU could also increase the transduction efficiency of
AAV vectors in MEFs. We reasoned that HU would promote
AAV trafficking into the nucleus, and would result in higher
transduction efficiency in KO MEFs compared with that in WTFig. 3. (A) Comparative analyses of the effect of HU treatment on the transduction e
WT, HE, and KO mice. Cells were mock-treated or treated with 10 mM or 40 mM HU
single-stranded recombinant AAV-lacZ vectors. Forty-eight hours post-infection, β-
reporter assay according to the manufacturer's instructions. (B) Southern blot analys
FKBP52 WT, HE, and KO mice without (Lanes 1–6) and with (Lanes 7–12) HU tre
AAV2-lacZ for 48 h at 37 °C. Low Mr DNAwas isolated and analyzed by Southern b
the viral single-stranded DNA genomes. (C) Quantitative analyses of cytoplasmic and
KO mice, with and without HU-treatment. *P < 0.001 versus control and KO-MEFMEFs because the absence of FKBP52 in the former would
facilitate viral second-strand DNA synthesis. Each of the
genotype cells was either mock-treated or treated with 10 mM
or 40 mM HU for 12 h prior to AAV-mediated transduction,
and transgene expression was determined 48 h post-transduc-
tion. These results are shown in Fig. 3A. It is evident that
treatment with HU did increase the AAV transduction
efficiency ∼15–25-fold, in a dose-dependent manner in WT
MEFs, and ∼7-fold in HE MEFs. Surprisingly, however, the
transduction efficiency in KO MEFs was increased by only
∼3–4-fold (P < 0.001).
Since in our previous studies we had determined that
impaired intracellular trafficking of AAV into the nucleus in the
NIH3T3 cell line limits high-efficiency transduction of these
cells (Hansen et al., 2000, 2001a), we reasoned that the lack of
significant increase in AAV transduction of KO MEFs might
also be due to inefficient transport of AAV from cytosol into the
nucleus. To corroborate this, nuclear and cytoplasmic fractions
of MEFs were obtained 48 h post-infection. Low Mr DNA was
isolated from these fractions and analyzed on Southern blots.
These results are shown in Fig. 3B. As can be seen, whereas
nearly 100% of the input AAV ssDNA was present in the
cytoplasmic fraction in MEFs from all three genotypes (Lanes
2, 4, 6), treatment with HU promoted nuclear transport of AAV
in each MEFs (Lanes 7, 9, 11). Densitometric analyses of thesefficiency of single-stranded, conventional AAV vectors in MEFs from FKBP52-
and either mock-infected or infected with 5 × 103 particles/cell of conventional,
galactosidase activity was measured by Galacto-Light Plus chemiluminiscence
es of cytoplasmic and nuclear distribution of AAV-lacZ genomes in MEFs from
atment. MEFs from each genotype were infected with ∼1 × 104 particles/cell of
lot hybridization using a 32P-labeled lacZ-specific DNA probe. ssDNA denotes
nuclear distribution of AAV-lacZ genomes in MEFs from FKBP52WT, HE, and
s.
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AAV DNA in the nuclear fraction increased to ∼58.5% in WT
MEFs, whereas in KO MEFs, the increase was only ∼28.1%.
These data suggest that, in the absence of FKBP52, treatment
with HU is not sufficient for the optimal transport of AAV into
the nucleus, which also correlates with the lower transduction
efficiency in KO MEFs.
HU treatment can also increase the transduction efficiency of
double-stranded, self-complementary AAV vectors in WT and
HE MEFs, but to a lesser extent in KO MEFs
In addition to promoting AAV intracellular trafficking, HU
can also dephosphorylate FKBP52 and increase AAV second-
strand DNA synthesis (Hansen et al., 2001a, 2001b; Qing et
al., 1998; Zhong et al., 2004c). In order to determine whether
the observed lack of increase in the transduction efficiency of
AAV vectors in KO MEFs following HU treatment was
related to viral second-strand DNA synthesis, we utilized
double-stranded, self-complementary AAV (scAAV) vectors
that obviate the need for viral second-strand DNA synthesis
(McCarty et al., 2001; Wang et al., 2003). Transduction
efficiency of scAAV-EGFP vectors was evaluated 48 h post-
infection in WT, HE, and KO MEFs, with and without prior
treatment with 40 mM HU. These results are shown in Fig.
4A. As can be seen, although scAAV vectors bypass the
requirement of viral second-strand DNA synthesis, the
transduction efficiency of these vectors in MEFs of all the
three genotypes was still very low, but could be increased by
HU treatment. Quantitative analyses of these data, shown in
Fig. 4B, indicated that HU treatment increased scAAV vector
transduction efficiency in WT MEFs ∼23-fold, but only ∼4-
fold in KO MEFs (P < 0.001). These data suggest that the
observed differential transduction efficiency of AAV vectors
in WT and KO MEFs, following HU treatment, is not directly
related to viral second-strand DNA synthesis.Fig. 4. (A) Comparative analyses of the effect of HU treatment on the transduction
FKBP52-WT, HE, and KO mice. Cells were mock-treated or treated with 40 mM HU
scAAV-EGFP vectors. Transgene expression was detected by fluorescence microscop
scAAV transduction efficiency. Images from three visual fields were analyzed quanti
area of green fluorescence (pixel2) per visual field (mean ± SD). *P < 0.001 versus coDeliberate expression of FKBP52 in KO MEFs restores the
normal response to HU-induced increase in AAV transduction
efficiency
To further evaluate the role of FKBP52 in AAV-mediated
transduction of MEFs, we generated a eukaryotic expression
plasmid containing the human FKBP52 gene under the
control of the Rous sarcoma virus promoter (pRSV-
hFKBP52). Since murine and human FKBP52 share 95%
homology (Sanchez et al., 1990; Schmitt et al., 1993), we
reasoned that expression of its human counterpart might be
functional in KO MEFs. KO cells were stably transfected
with this plasmid to generate KO-T cells, and the levels of
expression of FKBP52 were detected by Western blot
analyses. These data are shown in Fig. 5A. Densitometric
scanning of lumigraphs revealed that the level of expression
of FKBP52 in KO-T cells was between the levels of WT and
that of HE MEFs. In the next set of experiments, KO and
KO-T MEFs were either mock infected or infected with
recombinant AAV-lacZ vectors with or without prior
treatment with HU, and transgene expression was evaluated
48 h post-infection. These results are shown in Fig. 5B. It is
evident that, consistent with our previous data, AAV
transduction efficiency was low in KO MEFs (Panel b), and
HU treatment had little effect (Panel c). The transduction
efficiency was also low in KO-T cells (Panel e), but was
significantly increased following HU treatment (Panel f).
Nuclear and cytoplasmic fractions of KO and KO-T cells
were obtained 48 h post-infection, low Mr DNA was isolated
from these fractions and analyzed on Southern blots. These
results are shown in Fig. 5C. It is evident that, consistent with
our previous data, nearly 100% of the input AAV ssDNA was
present in the cytoplasmic fraction in KO (Lane 1) as well as
in KO-T (Lane 3) cells, treatment with HU promoted nuclear
transport of AAV in both cell types (Lanes 6, 8). Densi-
tometric analyses of these data, shown in Fig. 5D, indicatedefficiency of double-stranded, self-complementary AAV vectors in MEFs from
and either mock infected or infected with 5 × 103 particles/cell of recombinant
y 48 h post-infection. Original magnification 100×. (B) Quantitative analyses of
tatively by ImageJ analysis software. Transgene expression was assessed as total
ntrol, and P < 0.01 versus KOMEFs, **P < 0.001 versus control and KOMEFs.
Fig. 5. (A) Western blot analysis for the expression of FKBP52 in MEFs from FKBP52 WT, HE, and KO mice, and in KO cells stably transfected with an FKBP52
expression plasmid (KO-T). (B) Comparative analyses of AAV-mediated transduction efficiency in KO and KO-T cells. Cells were either mock-infected or infected
with 5 × 103 particles/cell recombinant AAV-lacZ vectors under identical conditions. (C) Southern blot analyses of cytoplasmic and nuclear distribution of AAV-lacZ
genomes in KO and KO-T cells, with and without HU treatment. (D) Quantitative analyses of the data in panel C.
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tion increased from ∼27.2% in KO cells to ∼61.9% in KO-T
cells. Thus, FKBP52 is able to restore normal response to HUFig. 6. Western blot analyses for interaction of AAV capsids with FKBP52. 293
cells were mock-transfected (Lane 1) or triple-transfected with pAAV-hrGFP,
pHelper, and pAAV2-RC plasmids (Lanes 2 and 3) to generate recombinant
AAV-GFP vectors. Cells were harvested 72 h post-transfection, cytoplasmic
fractions isolated, and immunoprecipitated with A20 antibodies (Lanes 1 and 2),
or normal mouse IgG (Lane 3), and probed with anti-B1 AAV antibodies (top
panel), anti-dynein intermediate chain (IC) antibodies (middle panel), and anti-
FKBP52 antibodies (bottom panel).treatment for AAV-mediated transgene expression in FKBP52-
KO MEFs.
Intact AAV capsids associate with FKBP52
We next examined whether FKBP52 also interacts with
intact AAV particles to facilitate intracellular trafficking.
However, these studies could not be performed in MEFs in
view of their low infection as well transfection efficiency, for
which 293 cells were used instead. Cells were either mock-
transfected or co-transfected with the following three plas-
mids: recombinant AAV vector (pAAV-hrGFP), an adenovirus
helper (pHelper), and an AAV helper (pAAV2-RC) to gene-
rate AAV-GFP vectors. Cells were harvested 72 h post-trans-
fection by scraping, and resuspended in a hypotonic buffer.
Cytoplasmic fraction was isolated by homogenization in a
tight-fitting Duall tissue grinder. Equivalent amounts of
cytoplasm were immunoprecipitated with A20 antibodies,
which specifically recognize only intact AAV particles with a
defined three-dimensional structure (Wistuba et al., 1997;
Wobus et al., 2000), and analyzed on Western blots. Immu-
noprecipitation with normal mouse IgG antibodies was
performed as a negative control. These results are shown in
Fig. 6. As can be seen, intact AAV capsids associate with
FKBP52 as well as dynein, known to interact with FKBP52
(Wochnik et al., 2005). These data document that FKBP52
acts as an accessory protein and may be involved in intr-
acellular trafficking of AAV directly or indirectly through
dynein.
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It is now firmly established that the viral second-strand
DNA synthesis is a major rate-limiting step in AAV-
mediated transgene expression, and that a cellular protein,
FKBP52, is a negative regulator of this step in the virus life
cycle (Ferrari et al., 1996; Fisher et al., 1996; Mah et al.,
1998; Qing et al., 1997, 1998, 2001, 2003; Zhong et al.,
2004a, 2004b, 2004c, 2004d). Although at first glance it
seemed intuitive that removal of FKBP52 from cells would
augment AAV second-strand DNA synthesis, and conse-
quently, transgene expression, our experimental analyses
with cells derived from FKBP52-KO mice, in which
FKBP52 was completely absent, documented that the
transduction efficiency of AAV vectors was in fact
significantly less pronounced than anticipated (Zhong et al.,
2004a, 2004b, 2004c). Counter-intuitively, over-expression of
FKBP52 led to a significant increase in the AAV transduction
efficiency in a variety of murine and human established cell lines
(Qing et al., 2001).
Since the level of expression of endogenous FKBP52 in
semi-permissive murine NIH3T3 cells was found to be
significantly lower than that in permissive human 293 cells
(data not shown), we wished to determine whether FKBP52
plays an additional role in AAV-mediated transduction in
primary murine cells. This was also of interest since in our
previous studies, we focused our efforts on the function of
FKBP52 localized in the nucleus, but FKBP52 is a cellular
chaperone, and it is also localized in the cytoplasm, where it co-
localizes with microtubules (Czar et al., 1994a, 1994b; Perrot-
Applanat et al., 1995). Although the amount of FKBP52 in the
cytoplasm is less than that in the nucleus, it plays crucial roles
in intracellular trafficking and/or nuclear transport of a number
of cellular and viral proteins, and a number of studies have
focused on the function of cytoplasmic FKBP52 (Czar et al.,
1994a, 1994b; Denny et al., 2005; Perrot-Applanat et al., 1995;
Pratt, 1998; Pratt et al., 1999, 2004; Pratt and Toft, 1997;
Wochnik et al., 2005; Wu et al., 2004).
Our previous studies have demonstrated that impaired
intracellular trafficking of AAV vectors limits efficient
transduction of murine cells, both established and primary,
and treatment with HU increased AAV-mediated transduction
efficiency in these cells by promoting nuclear transport of AAV
(Hansen et al., 2001a; Zhong et al., 2004c). Our previous
studies have also documented that AAV could infect purified
nuclei from human and murine cells, and in both instances,
could undergo viral uncoating and second-strand DNA
synthesis (Hansen et al., 2001b). Taken together, these studies
suggested that a major obstacle to efficient transduction of
murine fibroblasts by AAV vectors might exist in the cytoplasm.
Thus, murine fibroblasts seemed to be a suitable model to study
the intracellular fate of AAV vectors.
Large particles of more than 500 Å, such as viruses and
endosomes, are difficult to diffuse in the cytoplasm (Seksek
et al., 1997). Microtubules and microfilaments not only serve
as diffusion barriers but also act as “highways” to facilitate
the trafficking of these particles to specific destinations suchas the nucleus. Details of the intracellular pathway used by
AAVare now beginning to be fully understood (Bartlett et al.,
2000; Douar et al., 2001; Duan et al., 1999; Hansen et al.,
2000, 2001a; Lux et al., 2005; Seisenberger et al., 2001;
Warrington et al., 2004; Xiao et al., 2002). Some information
is available on the relation between AAV intracellular
trafficking and microtubules. For example, nocodazole-
treatment to depolymerize microtubules prior to AAV
infection has been shown to result in >95% reduction in the
nuclear accumulation of AAV, and cytochalasin B, which
disrupts microfilaments, has also been demonstrated to lead
to a dramatic reduction of >90% in the nuclear accumulation
of AAV (Sanlioglu et al., 2000). Trafficking on microtubules
destined for either the cell center or the apical domains uses a
cytoplasmic protein, dynein, since all endosome mobility
ceased when dynein function was disrupted by the use of a
mutant dynein heavy chain allele (Mallik and Gross, 2004;
Murray and Wolkoff, 2003; Welte, 2004). Previous studies
have shown that cytoplasmic dynein is less efficient and
robust in achieving the comparable function to the other
motors; and that it requires a number of accessory proteins as
well as multiple dyneins functioning together (Welte, 2004).
Information on the role of dynein in intracellular trafficking
of parvoviruses is beginning to emerge (Suikkanen et al.,
2002). For example, Xu et al. (2005) have reported that
inefficient entry of AAV into NIH3T3 cells could be
overcome by inserting a motif in the capsid predicted to
promote binding to the LC8 subunit of the dynein motor
complex. Additional studies have also documented that
FKBP52 can bind either directly or via a linker protein with
the cytoplasmic dynein; the PPIase domain fragment of
FKBP52 interacts with dynein, and provides a link between
the glucocorticoid receptor-HSP90 heterocomplex and cyto-
plasmic dynein for retrograde movement along microtubules
(Galigniana et al., 2001). Unfortunately, virtually nothing is
known about the role of FKBP52 on AAV intracellular
trafficking. In our current studies, the association of AAV
capsids with FKBP52 and dynein could be documented by
co-precipitation with A20 antibodies, which specifically
recognize only intact AAV particles with a defined three-
dimensional structure. Although our data provide only
indirect evidence for the role of FKBP52 as a nuclear
chaperone for AAV in MEFs since it remains possible that
the observed interaction between FKBP52, dynein, and AAV
might be due to the combined effects of HU and FKBP52.
However, since co-immunoprecipitation assays were carried
out in the absence of HU in 293 cells, we believe that the
observed interactions between FKBP52, dynein, and AAV
are direct. Additional co-localization studies involving
confocal microscopy will be needed to corroborate these
observations.
AAV vectors failed to gain entry into the nucleus, and
consequently failed to transduce primary murine fibroblasts.
Complete removal of FKBP52 did not lead to increased
transgene expression in these cells. However, FKBP52
facilitated the nuclear transport of AAV in the presence of HU
in murine cells. We hypothesize that FKBP52 plays a dual role
290 W. Zhao et al. / Virology 353 (2006) 283–293in the life cycle of AAV: the cytoplasmic FKBP52, presumably
in its unphosphorylated form, helps facilitate the intracellular
transport of the virus; and the nuclear FKBP52, in its
phosphorylated form, strongly inhibits the viral second-strand
DNA synthesis.
In sum, in addition to interacting with the D-sequence in the
AAV ITR and inhibiting viral second-strand DNA synthesis,
FKBP52, being a cellular chaperone protein, also facilitates
intracellular trafficking of AAV. It is of interest to further
explore whether the phosphorylation status of FKBP52 is a
determining factor. A better understanding of the underlying
molecular mechanism of intracellular trafficking of AAV should
have important implications in the optimal use of recombinant
AAV vectors in human gene therapy.
Materials and methods
Cells, viruses, and plasmids
Murine embryo fibroblasts (MEFs) were cultured as
previously described (Horak and Flechon, 1998; Mukherjee
et al., 1984). In brief, 12–14 day old embryos were obtained,
and a small amount of tissue was used for PCR analysis to
detect the FKBP52 genotypes. Fibroblasts were derived from
embryos by drawing each embryo through a 10 ml syringe
fitted with an 18 gauge needle. After washing, the cells were
cultured in 10 cm tissue culture dishes in MEF growth media
consisting of DMEM/F12 media (Gibco, Carlsbad, CA)
containing 10% fetal bovine serum and 1% (by volume)
100× stock solution of antibiotics (10,000 U of penicillin plus
10,000 μg of streptomycin) supplemented with 2 mM L-
glutamine. MEFs were immortalized at passage 3 following
infection with wild-type SV40 virus at a multiplicity of
infection (MOI) of 50. Immortalization had no significant
effect on AAV-lacZ transduction efficiency (data not shown).
Highly purified stocks of a recombinant AAV2 vector
containing the β-galactosidase (lacZ) reporter gene driven by
the cytomegalovirus (CMV) immediate-early promoter (AAV2-
lacZ) were obtained from Applied Viromics LLC, Fremont, CA.
Self-complementary recombinant AAV2 vectors containing the
CMV promoter-driven EGFP (scAAV2-EGFP) were generous-
ly provided by Dr. R. Jude Samulski, University of North
Carolina at Chapel Hill. A recombinant expression plasmid
containing the Rous sarcoma virus (RSV) promoter-driven
human FKBP52 cDNA (pRSV-hFKBP52) was constructed by
standard cloning methods.
Recombinant AAV2-mediated transduction assays
Approximately 8 × 104 or 3 × 105 MEFs were plated in each
well in 12-well or 6-well plates, respectively, and incubated at
37 °C for 12 h. Cells were washed once with DMEM/F12 media
and then infected at 37 °C for 2 h with mock and 5 × 103
particles per cell of recombinant AAV2-lacZ or scAAV2-EGFP
as described previously (Qing et al., 1997, 1998, 1999, 2001,
2003). Forty-eight hours after AAV2-lacZ infection, cells were
fixed and stained with X-gal (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside) and the blue cells were counted, or β-
galactosidase activity was measured by Galacto-Light Plus
chemiluminiscence reporter assay (Applied Biosystems, Foster
City, CA) according to the manufacturer's instructions. Data
were expressed as relative light units (RLU) per microgram of
total protein and were within the linear range of the assay. The
transduction efficiency of scAAV2-EGFP was measured by
GFP imaging using a Zeiss Axiovert 25 fluorescence micro-
scope (Carl Zeiss, Inc., Thornwood, NY). Images from three
visual fields of mock-infected and vector-infected MEFs cells
48 h post-injection were analyzed quantitatively by ImageJ
analysis software (NIH, Bethesda, MD). Transgene expression
was assessed as total area of green fluorescence (pixel2) per
visual field (mean ± SD).
Preparation of whole cell extracts (WCEs) and electrophoretic
mobility-shift assays (EMSA)
WCEs from MEFs were prepared according to the method
of Muller (1987). Total protein concentration was determined
by the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA), and
the extracts were frozen in liquid N2 and stored at −70 °C.
EMSA were performed as described previously (Qing et al.,
1997, 1998, 2001, 2003; Zhong et al., 2004d). Briefly, DNA-
binding reactions were performed in a volume of 20 μl with
2 μg of poly (dI-dC), 2 μg of bovine serum albumin, and 12%
glycerol in Tris buffer (10 mM Tris–HCl, 0.5 mM dithio-
threitol, 25 mM NaCl, 5 mM MgCl2, 0.05% Nonidet P-40
[NP40], pH 8.0). Ten micrograms of protein of each WCEs was
pre-incubated for 10 min at 25 °C followed by the addition of
10,000 cpm of 32P-labeled D-sequence synthetic oligonucleo-
tide (5′-AGGAACCCCTAGTGATGGAG-3′) in the reaction
mixture. The binding reaction was allowed to proceed for
30 min at 25 °C. Bound complexes were separated from the
free probe on low ionic strength 4% polyacrylamide gels with
Tris–glycine/EDTA buffer, pH 8.5, containing 50 mM Tris–
HCl, 380 mM glycine, and 2 mM EDTA. Following
electrophoresis, the gel was dried in vacuum and autoradio-
graphed using Kodak X-Omat film at −70 °C.
Southern blot analyses for AAV internalization
Approximately 3 × 106 MEFs from each genotype were
either mock-infected or infected with 3 × 103 particles/cell of
AAV2-lacZ for 2 h at 37 °C after which cells were treated with
0.01% trypsin and washed extensively with PBS to remove any
adsorbed and unadsorbed virus particles. Low Mr DNA was
isolated and electrophoresed on 1% agarose gels followed by
Southern blot hybridization with a 32P-labeled lacZ-specific
DNA probe as described previously (Hansen et al., 2000,
2001a).
Isolation of nuclear and cytoplasmic fractions from MEFs and
Southern blot analyses for AAV intracellular trafficking
Nuclear and cytoplasmic fractions from MEFs were
isolated as described previously (Hansen et al., 2000, 2001a;
291W. Zhao et al. / Virology 353 (2006) 283–293Zhong et al., 2004c). Briefly, MEFs mock infected or infected
with the recombinant AAV-lacZ vectors were washed twice
with PBS. The cell pellets were gently resuspended in 200 μl
of homogenization buffer (0.25 M sucrose, 10 mM triethano-
lamine, pH 7.6, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl
fluoride [PMSF]) and incubated on ice for 5 min, after which
10 μl of 10% NP-40 was added to each tube and cells were
observed under a light microscope for about 2 min. The
samples were then mixed gently and centrifuged for 5 min at
500 rpm at 4 °C. The supernatants (cytoplasmic fraction) were
decanted and stored on ice. The pellets (nuclear fractions)
were washed twice with 1 ml of homogenization buffer and
stored on ice. The purity of each fraction was determined to be
>95%, as measured by the absence of acid phosphatase
activity (nuclear fractions) and the absence of histone H3
(cytoplasmic fractions) as described previously (Hansen et al.,
2000, 2001a; Zhong et al., 2004c). Low Mr DNA samples
from nuclear and cytoplasmic fractions were isolated and
electrophoresed on 1% agarose gels followed by Southern blot
as described above. Densitometric scanning of autoradio-
graphs, for the quantitation of relative amounts of viral
genomes, was evaluated with ImageJ analysis software.
Stable transfection with FKBP52 expression plasmids
Approximately 4 × 105 MEFs from FKBP52-KO mice were
seeded into each well in a 6-well plate in DMEM/F12 media
(Gibco, Carlsbad, CA) containing 10% fetal bovine serum for
24 h prior to transfection. Four micrograms of pRSV-FKBP52
was added to cells using Lipofectamine 2000 Reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer's
instructions. Cells were cultured in the selective media
containing 300 mg/ml hygromycin (Invitrogen) 48 h after
transfection. Clones containing FKBP52 vectors were obtained
after 28 days of selection.
Immunoprecipitations and Western blot analyses
To determine the levels of FKBP52 in MEFs from FKBP52-
WT, HE, and KO mice, and in MEFs from FKBP52-KO mice
stably transfected with FKBP52 expression plasmid, approxi-
mately 3 × 106 cells were seeded in culture dishes, and 24 h
later, WCEs were prepared. Total protein concentrations were
determined using the Bio-Rad protein assay kit, and 40 μg of
protein was separated by SDS–polyacrylamide gel electropho-
resis on a 10% polyacrylamide gel. After transfer to an
Immobilon-P membrane (Millipore, Bedford, MA), the mem-
brane was blocked at 25 °C for 1 h with 5% nonfat dry milk in
1× Tris-buffered saline (TBS; 20 mM Tris–HCl, pH 7.5,
150 mM NaCl), and 0.05% Tween 20, then incubated with a
1:500 dilution of anti-FKBP52 antibody for 1 h at 25 °C.
Following incubation with 1:5000 dilution of horseradish
peroxidase-coupled anti-rabbit IgG antibody for at 25 °C 1 h
and protein bands were visualized with the ECL-Plus
chemiluminiscence detection kit (Amersham Biosciences,
Piscataway, NJ) according to the instructions provided by the
manufacturer.For immunoprecipitation, five 150 mm plates 293 cells were
triple transfected by pAAV-hrGFP, pHelper, and pAAV2-RC to
produce AAV vector with lipofectamine, and the cells were
harvested at 72 h post-transfection by scraping and resuspended
in 2 ml hypotonic buffer (20 mM HEPES pH 7.5, 5 mM KCl,
0.5 mM MgCl2, 1 mM DTT, 0.1 mM PMSF, 2 mM pepstatin
A), and the cytoplasm was isolated by homogenization in a
tight-fitting Duall tissue grinder until about 80% cell lysis was
achieved as monitored by trypan blue. Equivalent amounts of
cytoplasm were cleared of nonspecific binding by incubation
with 0.25 mg of normal mouse IgG together with 20 μl of
protein G-agarose beads for 60 min at 4 °C in an orbital shaker.
After pre-clearing, 2 μg of A20 antibody (mouse IgG) or 2 μg of
normal mouse IgG (as a negative control) was added and
incubated at 4 °C for 1 h, followed by precipitation with protein
G-agarose beads at 4 °C for 12 h in the shaker. Pellets were
collected by centrifugation at 2500 rpm for 5 min at 4 °C and
washed four times with phosphate-buffered saline. After the
final wash, the supernatant was aspirated and discarded, and the
pellet was resuspended in equal volume of 2× SDS sample
buffer. Twenty microliters of resuspended pellet solutions was
used for Western blotting with anti-B1, anti-FKBP52 and anti-
dynein intermediate chain antibodies (Sigma, USA).
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